Ironwood Pharmaceuticals Non-GAAP EPS of -$0.01 misses by $0.02, revenue of $47.71M misses by $3.22M
Source: SeekingAlpha
2026-02-25 07:15:33 ET
2026 Guidance... (February 2026) | |
U.S. LINZESS Net Sales | $1.125 - $1.175 billion Driven by improved net price and low-single digit percentage demand growth |
Total Revenue 1 | $450 - $475 million (vs. consensus of $410.5M) |
Adjusted EBITDA 2 | >$300 million |
Read the full article on Seeking Alpha
For further details see:
Ironwood Pharmaceuticals Non-GAAP EPS of -$0.01 misses by $0.02, revenue of $47.71M misses by $3.22M
Ironwood Pharmaceuticals Inc.
NASDAQ: IRWD
IRWD Trading
5.29% G/L:
$3.785 Last:
1,088,304 Volume:
$3.70 Open:
IRWD Latest News
IRWD Stock Data
$754,015,529
142,018,459
0.3%
66
N/A
Pharmaceuticals
Healthcare
US
Boston
